349 related articles for article (PubMed ID: 24477463)
1. [Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].
Schreiber J; Kopp MV; Korn S; Taube C; Buhl R
Pneumologie; 2014 Mar; 68(3):187-92. PubMed ID: 24477463
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
[TBL] [Abstract][Full Text] [Related]
3. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
4. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.
Steiss JO; Schmidt A; Nährlich L; Zimmer KP; Rudloff S
Allergy Asthma Proc; 2012; 33(1):77-81. PubMed ID: 22370532
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
Rottem M
J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.
Kornmann O; Watz H; Fuhr R; Krug N; Erpenbeck VJ; Kaiser G
Pulm Pharmacol Ther; 2014 Aug; 28(2):149-53. PubMed ID: 24657236
[TBL] [Abstract][Full Text] [Related]
8. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
9. [Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].
Klyucheva M; von Berg A; Gappa M; Suerbaum C; Berdel D
Pneumologie; 2013 Apr; 67(4):233-7. PubMed ID: 23576201
[TBL] [Abstract][Full Text] [Related]
10. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
11. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
[TBL] [Abstract][Full Text] [Related]
12. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
[TBL] [Abstract][Full Text] [Related]
13. Plasmapheresis prior to omalizumab administration in a 15-year-old boy with severe asthma and very high IgE levels: sustained effect over 2 years.
Kerzel S; Zemlin M; Rogosch T; Ollert M; Renz H; Klaus G; Maier RF
Klin Padiatr; 2011 Nov; 223(6):356-9. PubMed ID: 22012605
[TBL] [Abstract][Full Text] [Related]
14. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
15. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.
Molimard M; Mala L; Bourdeix I; Le Gros V
Respir Med; 2014 Apr; 108(4):571-6. PubMed ID: 24565601
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
[TBL] [Abstract][Full Text] [Related]
17. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
[TBL] [Abstract][Full Text] [Related]
18. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
Nowak D
Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
[TBL] [Abstract][Full Text] [Related]
19. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab in the treatment of chronic urticaria.
Francés L; Leiva-Salinas M; Silvestre JF
Actas Dermosifiliogr; 2014; 105(1):45-52. PubMed ID: 23938072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
